Clinicopathological characteristics and outcome of chinese patients with thrombotic thrombocytopenic purpura-Hemolytic uremic syndrome: A 9-year retrospective study

Nephron - Clinical Practice

Volumn 112, Issue 3, 2009, Pages

  Zhang, Wen ^a   Shi, Hao ^a   Ren, Hong ^a   Shen, Ping Yan ^a   Pan, Xiao Xia ^a   Li, Xiao ^a   Chen, Yong Xi ^a   Xu, Yao Wen ^a   Chen, Xiao Nong ^a   Zhu, Ping ^a   Chen, Nan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Hemolytic uremic syndrome; Kidney injury, acute; Plasmapheresis; Renal failure, acute; Systemic lupus erythematosus; Thrombotic thrombocytopenic purpura

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; HEMODIAFILTRATION; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; MALE; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; VASCULITIS;

ADOLESCENT; ADULT; CHILD; CHINA; COMORBIDITY; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65549107064     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218106     Document Type: Article

References (42)

1. Coppo P, Veyradier A, Durey MA, Fre-meaux-Bacchi V, Scrobohaci ML, Amesland F, Bussel A:Pathophysiology of thrombotic microangiopathies: current understanding (in French). Ann Med Interne (Paris) 2002;153:153-166.
2. Hosler GA, Cusumano AM, Hutchins GM:Thrombotic t hrombocy topenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med 2003;127:834- 839.
3. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, Raskob GE:ADAMTS13 activity in thrombotic throm-bocytopenic purpura-hemolytic uremic syndrome:relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003;102:60-68.
4. Tostivint I, Mougenot B, Flahault A, Vigneau C, Costa MA, Haymann JP, Sraer JD, Rondeau E:Adult haemolytic and uraemic syndrome:causes and prognostic factors in the last decade. Nephrol Dial Transplant 2002;17:1228-1234.
5. Elliott MA, Nichols WL:Thrombotic throm-bocytopenic purpura and hemolytic uremic syndrome. Mayo Clin Proc 2001;76:11 5 4-1162.
6. Hollenbeck M, Kutkuhn B, Aul C, Leschke M, Willers R, Grabensee B: Haemolyticuraemic syndrome and thrombotic-throm-bocytopenic purpura in adults:clinical findings and prognostic factors for death and end-stage renal disease. Nephrol Dial Transplant 1998;13:76-81.
7. George JN:How I treat patients with throm-botic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000;96:1223- 1229.
8. Bell WR, Braine HG, Ness PM, Kickler TS:Improved survival in thrombotic thrombo-cytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991;325:398-403.
9. Hayward CP, Sutton DM, Carter WH Jr, Campbell ED, Scott JG, Francombe WH, Shumak KH, Baker MA:Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura-hemolytic ure-mic sy ndrome. Arch Intern Med 1994;154:982-987.
10. Rock GA, Shumak KH, Buskard NA, Blanch-ette VS, Kelton JG, Nair RC, Spasoff RA:Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325:393-397.
11. Dervenoulas J, Tsirigotis P, Bollas G, Pappa V, Xiros N, Economopoulos T, Pappa M, Mellou S, Kostourou A, Papageorgiou E, Raptis SA:Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/ HUS):treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases. Ann Hematol 2000;79:66-72.
12. Elliott EJ, Robins-Browne RM, O'Loughlin EV, Bennett-Wood V, Bourke J, Henning P, Hogg GG, Knight J, Powell H, Redmond D:Nationwide study of haemolytic uraemic syndrome:clinical, microbiological, and ep-idemiological features. Arch Dis Child 2001;85:125-131.
13. Hochberg MC:Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Ar t hritis Rheum 1997;40:1725.
14. Lockshin MD:Update on antiphospholipid sy ndrome. Bu ll N YU Hosp Jt Dis 2006;64:57-59.
15. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, PG DEG, Koike T, Meroni PL, Reber G, Shoen-feld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA:International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
16. Allford SL, Hunt BJ, Rose P, Machin SJ:Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003;120:556-573.
17. Besbas N, Karpman D, Landau D, et al:A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. K idney Int 2006;70:423-431.
18. Cockcroft DW, Gault MH:Prediction of cre-atinine clearance from serum creatinine. Nephron 1976;16:31-41.
19. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P:Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs:the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204- R212.
20. Van Biesen W, Vanholder R, Lameire N:Defining acute renal failure:rifle and beyond. Clin J Am Soc Nephrol 2006;1:1314-1319.
21. George JN, Kremer Hovinga JA, Terrell DR, Vesely SK, Lammle B:The Oklahoma thrombotic thrombocytopenic purpura-he-molytic uremic syndrome registry:the Swiss connection. Eur J Haematol 2008;80:277- 286.
22. Zimmerhackl LB, Scheiring J, Prufer F, Taylor CM, Loirat C:Renal transplantation in HUS patients with disorders of complement regulation. Pediatr Nephrol 2007;22:10-16.
23. Siegler RL, Pavia AT, Hansen FL, Christof-ferson RD, Cook JB:Atypical hemolytic-ure-mic syndrome:a comparison with postdiar-rheal disease. J Pediatr 1996;128:505-511.
24. Gordjani N, Sutor AH, Zimmerhackl LB, Brandis M:Hemolytic uremic syndromes in childhood. Semin Thromb Hemost 1997;23:281-293.
25. Bianchi V, Robles R, Alberio L, Furlan M, Lammle B:Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytope-nic disorders:a severely deficient activity is specific for thrombotic thrombocytopenic pur pura. Blood 2002;100:710-713.
26. Mori Y, Wada H, Gabazza EC, Minami N, Nobori T, Shiku H, Yagi H, Ishizashi H, Mat-sumoto M, Fujimura Y:Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of VWF-cleaving protease activity. Transfusion 2002;42:572-580.
27. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Schar-rer I, Aumann V, Mittler U, Solenthaler M, Lammle B:Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-1584.
28. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP:Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies:a study of 111 cases. Blood 2001;98:1765-1772.
29. Remuzzi G, Galbusera M, Noris M, Canciani MT, Daina E, Bresin E, Contaretti S, Caprioli J, Gamba S, Ruggenenti P, Perico N, Mannucci PM:Von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocyto-penic purpura and hemolytic uremic syndrome. Blood 2002;100:778-785.
30. McMinn JR, George JN:Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic ure-mic syndrome during pregnancy. J Clin Apher 2001;16:202-209.
31. George JN:The association of pregnancy with thrombotic thrombocytopenic purpu-ra-hemolytic uremic syndrome. Curr Opin Hematol 2003;10:339-344.
32. E spinosa G, Bucciarelli S, Cervera R, Lozano M, Reverter JC, de la Red G, Gil V, Ingelmo M, Font J, Asherson R A:Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis 2004;63:730-736.
33. Bosch T, Wendler T:Extracorporeal plasma treatment in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome:a review. Ther Apher 2001;5:182-185.
34. Ruggenenti P, Noris M, Remuzzi G:Throm-botic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytope-nic purpura. Kidney Int 2001;60:831-846.
35. Rock GA:Management of thrombotic thrombocytopenic purpura. Br J Haematol 2000;109:496-507.
36. Durand JM, Lefevre P, Kaplanski G, Telle H, Soubeyrand J: Vincristine for thrombotic thrombocytopenic purpura. Lancet 1992;340:977-978.
37. Lefevre P, Durand JM, Blanc AP, Guidon C, Peyron C, Alazia M, Prince-Zucchelli MA, Mongin M:Value of vincristine in the treatment of thrombotic thrombopenic purpura (in French). Presse Med 1986;15:77.
38. Morel-Maroger L, Kanfer A, Solez K, Sraer JD, Richet G:Prognostic importance of vascular lesions in acute renal failure with mi-croangiopathic hemolytic anemia (hemo-lytic-uremic syndrome):clinicopathologic study in 20 adults. Kid ney Int 1979;15:548- 558.
39. Descombes E, Droz D, Drouet L, Grunfeld J P, Lesavre P:Renal vascular lesions in lupus nephritis. Medicine (Ba ltimore) 1997;76:355-368.
40. Hughson MD, Nadasdy T, McCarty GA, Sholer C, Min KW, Silva F:Renal thrombot-ic microangiopathy in patients with systemic lupus erythematosus and the antiphos-pholipid syndrome. Am J Kidney Dis 1992;20:150-158.
41. Pollock KG, Young D, Beattie TJ, Todd WT:Clinical surveillance of thrombotic micro-angiopathies in Scotland, 2003-2005. Epidemiol Infect 2008;136:115-121.
42. Thompson CE, Damon LE, Ries CA, Linker CA:Thrombotic microangiopathies in the 1980s:clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood 1992;80:1890-1895.